KIT and small cell lung carcinoma: Since overexpression of c-Kit has been reported in 70% of SCLC patients [23,24], determination of c-Kit and PD-L1 expression using immunohistochemical staining in the tissues of SCLC patients may increase the therapeutic efficacy by combination treatment with anti-c-Kit ADC plus anti-PD-L1.